Multiple Myeloma

Denosumab is noninferior to zoledronic acid at delaying skeletal-related events for patients with multiple myeloma.

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the International Myeloma Working Group’s recently released updated consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma.

George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of Medicine (Hematology and Medical Oncology) at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses induction therapy for multiple myeloma.

Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.

The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

As the FDA considers a supplemental biologics license application for 2 daratumumab-based triplet regimens in multiple myeloma, the results for 1 of the pivotal phase III studies supporting the sBLA have been published in The New England Journal of Medicine.

Shaji Kumar, MD, discusses the roles that the recently released updated consensus criteria by the International Myeloma Working Group and MRD testing will play going forward in multiple myeloma.

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

Philip McCarthy, BA, MD, professor of oncology and internal medicine director, blood and marrow transplant program, Roswell Park Cancer Institute discusses maintenance therapy for multiple myeloma patients that are eligible for transplant.

Carfilzomib did not improve progression-free survival compared with bortezomib when used in combination with melphalan and prednisone as a treatment for transplant ineligible patients with newly diagnosed multiple myeloma.

The CHMP has recommended a conditional approval for ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.

Despite multiple therapeutic advances in recent years, proteasome inhibitors remain a cornerstone of therapy for multiple myeloma, both newly diagnosed and relapsed and refractory disease.

Almost 90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the role of stem cell transplant in treating patients with multiple myeloma.

Selinexor (KPT-330) demonstrated promising clinical activity in patients with heavily pretreated multiple myeloma.

Maria-Victoria Mateos, MD, PhD, provides insight on a subanalysis of the TOURMALINE-MM1 trial, the impact of ixazomib's (Ninlaro's) approval, and the future of triplet combinations in the treatment multiple myeloma.

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.